Depression of thalamic metabolism by lorazepam is associated with sleepiness

Neuropsychopharmacology. 1995 Apr;12(2):123-32. doi: 10.1016/0893-133X(94)00068-B.

Abstract

Though it is well recognized that the pharmacological actions of benzodiazepines are mediated by facilitation of GABAergic neurotransmission, the consequences of these changes in regional brain function are not well understood. This study measured regional brain glucose metabolism using Positron Emission Tomography and 2-deoxy-2[18F]fluoro-D-glucose in normal controls (n = 21) investigated with and without lorazepam (30 micrograms/kg IV) and with flumazenil given after lorazepam (n = 9). Lorazepam markedly decreased metabolism in thalamus (23 +/- 8%) and occipital cortex (19 +/- 8%), and flumazenil partially reversed these changes. Changes in metabolic activity in thalamus were significantly correlated with lorazepam-induced sleepiness (r = .69, df 20, p < .0005) and there was a trend of an association between the reversal by flumazenil of lorazepam-induced change in thalamus and in sleepiness (r = .63, df 8, p = .07). Benzodiazepine-induced changes in thalamic activity may account for their sedative properties.

Publication types

  • Research Support, U.S. Gov't, Non-P.H.S.
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Adult
  • Cognition / drug effects
  • Deoxyglucose / analogs & derivatives
  • Deoxyglucose / metabolism
  • Depression, Chemical
  • Flumazenil / pharmacology
  • Fluorodeoxyglucose F18
  • Glucose / metabolism
  • Humans
  • Lorazepam / antagonists & inhibitors
  • Lorazepam / pharmacology*
  • Male
  • Middle Aged
  • Occipital Lobe / diagnostic imaging
  • Occipital Lobe / drug effects
  • Occipital Lobe / metabolism
  • Sleep* / drug effects
  • Thalamus / drug effects
  • Thalamus / metabolism*
  • Tomography, Emission-Computed

Substances

  • Fluorodeoxyglucose F18
  • Flumazenil
  • Deoxyglucose
  • Glucose
  • Lorazepam